English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
JSKN033
JSKN016
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
JSKN033
JSKN016
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
2023-01-05
Terms of Reference of the Remuneration Committee
2022-12-28
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF RESEARCH UPDATES ON KN046 AND KN026 AT THE SABCS 2022
2022-12-09
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
2022-12-06
Next Day Disclosure Return
2022-11-24
Next Day Disclosure Return
2022-11-16
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
2022-11-04
VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY NMPA FOR A PHASE IA/IB CLINICAL TRIAL OF JSKN003 FOR THE TREATMENT OF ADVANCED SOLID TUMORS
2022-10-27
GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME
2022-10-24
GRANT OF SHARE OPTIONS
2022-10-24
4
5
6
7
8
9
10
PREV
7/22
NEXT